当前位置: X-MOL 学术J. Antimicrob. Chemother. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19
Journal of Antimicrobial Chemotherapy ( IF 3.9 ) Pub Date : 2021-09-02 , DOI: 10.1093/jac/dkab321
Carolina Garcia-Vidal 1 , Rodrigo Alonso 1 , Ana M Camon 1 , Celia Cardozo 1 , Laia Albiach 1 , Daiana Agüero 1 , M Angeles Marcos 2, 3 , Juan Ambrosioni 1 , Marta Bodro 1 , Mariana Chumbita 1 , Lorena de la Mora 1 , Nicole Garcia-Pouton 1 , Gerard Dueñas 1 , Marta Hernandez-Meneses 1 , Alexy Inciarte 1 , Genoveva Cuesta 2, 3 , Fernanda Meira 1 , Laura Morata 1 , Pedro Puerta-Alcalde 1 , Sabina Herrera 1 , Montse Tuset 4 , Pedro Castro 5 , Sergio Prieto-Gonzalez 6 , Alex Almuedo-Riera 3, 7 , Josep Mensa 1 , José Antonio Martínez 1 , Gemma Sanjuan 1, 8 , J M Nicolas 5 , A del Rio 1 , José Muñoz 3, 7 , Jordi Vila 2, 3 , Felipe Garcia 1 , Alex Soriano 1
Affiliation  

The use of remdesivir has demonstrated a significant reduction in the time to recovery in patients with COVID-19. However, the impact on mortality is still controversial. Therefore, it is necessary to evaluate whether there is a specific subgroup of patients in whom an active antiviral therapy also reduces the mortality.

中文翻译:

瑞德西韦对 COVID-19 患者入院前症状持续时间的影响

瑞德西韦的使用已证明可显着缩短 COVID-19 患者的康复时间。然而,对死亡率的影响仍然存在争议。因此,有必要评估是否存在特定的患者亚组,在该亚组中,积极的抗病毒治疗也能降低死亡率。
更新日期:2021-09-03
down
wechat
bug